open access

Vol 83, No 4 (2012)
ARTICLES
Get Citation

Etanercept immunotherapy in women with a history of recurrent reproductive failure

Małgorzata Jerzak, Monika Ohams, Andrzej Górski, Włodzimierz Baranowski
Ginekol Pol 2012;83(4).

open access

Vol 83, No 4 (2012)
ARTICLES

Abstract

Objective: The aim of the study was to evaluate the effect of etanercept immunotherapy on peripheral natural killer (NK) cell activity in women with a history of recurrent miscarriage (RM) or failed in vitro fertilization (IVF). Materials and methods: Thirty nonpregnant women with reproductive failure and increased peripheral NK-cell number and/or activity before conception were studied. Women with reproductive failure received 4 doses (25 mg) of etanercept twice weekly before conception. Peripheral NK-cell activity before and after etanercept therapy in RM women was measured using flow cytometry. In addition, the peripheral blood NK-cell surface antigens- CD16- and CD56 and peripheral blood regulatory T cell (T reg) antigens- CD4- and CD25 were studied using flow cytometry, before treatment and 2 weeks after the last etanercept dose. Results: NK-cell activity was significantly decreased after etanercept therapy in the study women (P<.05). This effect was significantly higher in women with subsequent pregnancy success (P<.05), but not in those with pregnancy failure (P>.05). There were no significant differences in T reg level before and after etanercept therapy (P>0.05). Conclusion: Etanercept therapy might be effective treatment for women with increased NK-cell activity. Regulation of immune system activity may underlie the possible effect of such therapy.

Abstract

Objective: The aim of the study was to evaluate the effect of etanercept immunotherapy on peripheral natural killer (NK) cell activity in women with a history of recurrent miscarriage (RM) or failed in vitro fertilization (IVF). Materials and methods: Thirty nonpregnant women with reproductive failure and increased peripheral NK-cell number and/or activity before conception were studied. Women with reproductive failure received 4 doses (25 mg) of etanercept twice weekly before conception. Peripheral NK-cell activity before and after etanercept therapy in RM women was measured using flow cytometry. In addition, the peripheral blood NK-cell surface antigens- CD16- and CD56 and peripheral blood regulatory T cell (T reg) antigens- CD4- and CD25 were studied using flow cytometry, before treatment and 2 weeks after the last etanercept dose. Results: NK-cell activity was significantly decreased after etanercept therapy in the study women (P<.05). This effect was significantly higher in women with subsequent pregnancy success (P<.05), but not in those with pregnancy failure (P>.05). There were no significant differences in T reg level before and after etanercept therapy (P>0.05). Conclusion: Etanercept therapy might be effective treatment for women with increased NK-cell activity. Regulation of immune system activity may underlie the possible effect of such therapy.
Get Citation

Keywords

Rtanercept, in vitro fertilization, Nk-cell activity, recurrent miscarriage

About this article
Title

Etanercept immunotherapy in women with a history of recurrent reproductive failure

Journal

Ginekologia Polska

Issue

Vol 83, No 4 (2012)

Bibliographic record

Ginekol Pol 2012;83(4).

Keywords

Rtanercept
in vitro fertilization
Nk-cell activity
recurrent miscarriage

Authors

Małgorzata Jerzak
Monika Ohams
Andrzej Górski
Włodzimierz Baranowski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl